2-(苄氧基)-1-溴-4-氟苯 | 202857-88-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(苄氧基)-1-溴-4-氟苯
• 中文别名: 2-苄氧基-1-溴-4-氟苯
• 英文名称: 2-(benzyloxy)-1-bromo-4-fluorobenzene
• 英文别名: 1-bromo-4-fluoro-2-phenylmethoxybenzene
• CAS: 202857-88-3
• 化学式: C₁₃H₁₀BrFO
• 分子量: 281.124
• InChiKey: ZLVBPRJVAJMBHD-UHFFFAOYSA-N

物化性质

• 沸点：
  322.8±27.0 °C(Predicted)
• 密度：
  1.445±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Benzyloxy-1-bromo-4-fluorobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Benzyloxy-1-bromo-4-fluorobenzene
CAS number: 202857-88-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H10BrFO
Molecular weight: 281.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(苄氧基)-1-溴-4-氟苯 在 四(三苯基膦)钯 、 三氯化硼 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 4.5h， 生成 5-(4-fluoro-2-hydroxyphenyl)furan-2-carbaldehyde
  参考文献：
  名称：

  Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ

  摘要：

  Class I phosphoinositide 3-kinases (PI3Ks), in particular PI3K gamma, have become attractive drug targets for inflammatory and autoimmune diseases. Here, we disclose a novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3K gamma inhibitors. Structure-based design and X-ray crystallography of complexes formed by inhibitors bound to PI3K gamma identified key pharmacophore features for potency and selectivity. An acidic NH group on the thiazolidinedione moiety and a hydroxy group on the furan-2-yl-phenyl part of the molecule play crucial roles in binding to PI3K and contribute to class IB PI3K selectivity. Compound 26 (AS-252424), a potent and selective small-molecule PI3K gamma inhibitor emerging from these efforts, was further profiled in three different cellular PI3K assays and shown to be selective for class IB PI3K-mediated cellular effects. Oral administration of 26 in a mouse model of acute peritonitis led to a significant reduction of leukocyte recruitment.

  DOI：

  10.1021/jm0601598
• 作为产物：
  描述：

  溴甲苯 在 盐酸 、 potassium carbonate 作用下， 以 氘代丙酮 为溶剂， 以98%的产率得到2-(苄氧基)-1-溴-4-氟苯
  参考文献：
  名称：

  HIV INTEGRASE INHIBITORS

  摘要：

  本发明具有作为HIV整合酶抑制剂的化合物，因此在抑制HIV复制、预防及/或治疗HIV感染以及治疗艾滋病及/或艾滋病相关综合症方面具有用途。

  公开号：

  US20150225399A1

文献信息

• [EN] FLUOROIMIDAZOPYRIMIDINES AS GABA-A ALPHA 2/3 LIGANDS FOR DEPRESSION/ANXIETY<br/>[FR] ANTIDEPRESSEUR / ANXIOLITIQUES A BASE DE FLUOROIMIDAZOPYRIMIDINES SERVANT DE LIGANDS ALPHA 2/3 DES GABA-A
  申请人：MERCK SHARP & DOHME

  公开号：WO2004065388A1

  公开（公告）日：2004-08-05

  The present invention provides a compound formula (I), or a pharmaceutically acceptable salt thereof: wherein W is phenyl or pyridyl; X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an -NH- linkage or a group -OCnH2n-; Z represents an optionally substituted aryl or heteroaryl group; R1 represents hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -ORa, -SRa, -SORa, -SO2Ra, -SO2NRaRb, NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra, -CONRaRb or Cra=NORb; Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group; and n is zero, one, two or three; pharmaceutical compositions comprising it; its use in methods of treatment; use of it in the manufacture of medicaments to treat anxiety and/or depression; and methods of treatment for anxiety and/or depression using it.

  本发明提供了一个化合物公式(I)，或其药学上可接受的盐：其中W是苯基或吡啶基；X1代表氢、卤素、C1-6烷基、三氟甲基或C1-6烷氧基；X2代表氢或卤素；Y代表化学键、-NH-连接或-OCnH2n-基团；Z代表可选择取代的芳基或杂芳基；R1代表碳氢化合物、杂环基团、卤素、氰基、三氟甲基、硝基、-ORa、-SRa、-SORa、-SO2Ra、-SO2NRaRb、NRaRb、-NRaCORb、-NRaCO2Rb、-CORa、-CO2Ra、-CONRaRb或Cra=NORb；Ra和Rb独立地代表氢、碳氢化合物或杂环基团；n为零、一、二或三；包括它的药物组合物；其在治疗方法中的使用；将其用于制造治疗焦虑和/或抑郁症药物；以及使用它进行焦虑和/或抑郁症治疗的方法。
• [EN] TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2017058716A1

  公开（公告）日：2017-04-06

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.

  本文提供了包含所述化合物的药物组合物，用于治疗癌症或先天性疾病。具体的癌症和先天性疾病包括那些由YAP/TAZ介导的疾病。
• Substituted biphenyls
  申请人：Bayer Corporation

  公开号：US06218431B1

  公开（公告）日：2001-04-17

  Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1a and R1b independently represent (C1-C6) alkyl; R2 represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7 represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3 represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4 wherein R4 is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.

  具有胰高血糖素受体拮抗活性的取代联苯。所述化合物的结构式如下：其中R1a和R1b分别代表（C1-C6）烷基；R2代表（C1-C10）烷基或取代的（C1-C10）烷基，其中取代基独立地为1至3个-SR7；R7代表苯基，或取代的苯基，其中取代基独立地为1-5个卤素、三氟甲基、（C1-C6）烷基、（C1-C6）烷氧基、硝基、氰基或羟基；R3代表取代的（C1-C6）烷基，其中取代基为1-2个羟基；G代表从卤素、（C1-C6）烷基和OR4（其中R4为H或（C1-C6）烷基）组成的取代基；y为0或1-3的整数。还声明了含有这类化合物的药物组合物以及通过给予这类化合物治疗胰高血糖素介导疾病的方法。
• Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols
  作者：Stéphane G. Ouellet、Anna Bernardi、Remy Angelaud、Paul D. O’Shea

  DOI：10.1016/j.tetlet.2009.03.204

  日期：2009.7

  In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzene derivatives with various alcohols.

  在这封信中，我们描述了一种实用且高度选择性的方法，用于制备氟代芳基醚和差异取代的间苯二酚衍生物。该合成策略依赖于取代的二氟苯衍生物与各种醇的选择性S N Ar。
• NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE
  申请人：DAINIPPON SUMITOMO PHARMA CO., LTD.

  公开号：US20140121243A1

  公开（公告）日：2014-05-01

  A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): wherein A is CR 1E or a nitrogen atom, X—Y—Z is N—CO—NR 3A R 3B and the like, R 1A to R 1E are each independently a hydrogen atom and the like, R 2A to R 2D are each independently a hydrogen atom and the like, R 3A and R 3B are each independently an optionally-substituted C 3-10 cycloalkyl and the like, and n is 1 or 2 or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).

  一种用于治疗与中枢神经系统（CNS）和/或外周神经系统（PNS）中胆碱能特性相关疾病、与平滑肌收缩相关疾病、内分泌紊乱、神经退行性疾病等的药物，其中包括化合物Formula（I）：其中A为CR1E或氮原子，X—Y—Z为N—CO—NR3AR3B等，R1A到R1E各自独立地为氢原子等，R2A到R2D各自独立地为氢原子等，R3A和R3B各自独立地为选择性取代的C3-10环烷基等，n为1或2或其药学上可接受的盐，具有对α7烟碱乙酰胆碱受体（α7 nAChR）活性的强效调节作用。